For example, Vemurafenib (Zelboraf®) targeting BRAF V600E mutant protein is prescribed to treat melanoma patients with BRAF V600E mutation, and imatinib mesylate (Gleevec®) only targets the patients with BCR-ABL fusion proteins in their leukemia cells [22,23]. This evidence concerns the gene BRAF and leukemia.